Pine River Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pine River Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-17,500	Closed	-$1.91M	–	248
2016 Q4	$1.91M	Sell	17,500 -12,500	-42%	-$1.39M	0.07%	115
2016 Q3	$3.64M	Buy	30,000 +17,480	+140%	+$2.36M	0.06%	131
2016 Q2	$3.54B	Sell	12,520 -12,520	-50%	-$1.85M	39.45%	1
2016 Q1	$3.27M	Hold	25,040	–	–	0.05%	202
2015 Q4	$3.52M	Sell	25,040 -9,000	-26%	-$1.25M	0.05%	227
2015 Q3	$4.52M	Sell	34,040 -1,000	-3%	-$172K	0.06%	216
2015 Q2	$6.17M	Hold	35,040	–	–	0.07%	211
2015 Q1	$6.05M	Buy	35,040 +5,040	+17%	+$865K	0.07%	190
2014 Q4	$4.91M	Buy	+30,000	New	+$4.98M	0.06%	209

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Pine River Capital Management's JAZZ Position: Q1 2017 in Review

Pine River Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2017, closing a stake of 17,500 shares — an estimated $1.91M sold.

Pine River Capital Management first reported a position in JAZZ in Q4 2014 and held it in 9 quarters. The position peaked at $3.54B in Q2 2016. 306 funds tracked by Wall St. Rank hold JAZZ as of Q1 2017.

Pine River Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Pine River Capital Management sold 17,500 Jazz Pharmaceuticals shares in Q1 2017, an estimated $1.91M.
Pine River Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Pine River Capital Management's Jazz Pharmaceuticals position peaked at $3.54B in Q2 2016.
306 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2017.

Based on Pine River Capital Management's 13F filing for Q1 2017, filed 15 May 2017.